JP2009538607A - 患者が免疫療法に対する応答者であるかどうかを同定する方法 - Google Patents

患者が免疫療法に対する応答者であるかどうかを同定する方法 Download PDF

Info

Publication number
JP2009538607A
JP2009538607A JP2009512510A JP2009512510A JP2009538607A JP 2009538607 A JP2009538607 A JP 2009538607A JP 2009512510 A JP2009512510 A JP 2009512510A JP 2009512510 A JP2009512510 A JP 2009512510A JP 2009538607 A JP2009538607 A JP 2009538607A
Authority
JP
Japan
Prior art keywords
genes
identified
another embodiment
combination
symbol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009512510A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009538607A5 (enExample
Inventor
ブリチャード，ビンセント
クラーク，ジェイムズ，スコット
コシェ，ティエリー
ゴーリス，スワン，ロマン，ジャン−トマス
グルーセレ，オリビエ
レーマン，フレデリク
ルアヘド，ジャミラ
Original Assignee
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0610949A external-priority patent/GB0610949D0/en
Priority claimed from GB0700761A external-priority patent/GB0700761D0/en
Application filed by グラクソスミスクライン バイオロジカルズ ソシエテ アノニム filed Critical グラクソスミスクライン バイオロジカルズ ソシエテ アノニム
Publication of JP2009538607A publication Critical patent/JP2009538607A/ja
Publication of JP2009538607A5 publication Critical patent/JP2009538607A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2009512510A 2006-06-02 2007-05-31 患者が免疫療法に対する応答者であるかどうかを同定する方法 Pending JP2009538607A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0610949A GB0610949D0 (en) 2006-06-02 2006-06-02 Method
GB0700761A GB0700761D0 (en) 2007-01-15 2007-01-15 Method
PCT/EP2007/004915 WO2007140958A2 (en) 2006-06-02 2007-05-31 Method for identifying whether a patient will be responder or not to immunotherapy

Publications (2)

Publication Number Publication Date
JP2009538607A true JP2009538607A (ja) 2009-11-12
JP2009538607A5 JP2009538607A5 (enExample) 2010-07-08

Family

ID=38801855

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009512510A Pending JP2009538607A (ja) 2006-06-02 2007-05-31 患者が免疫療法に対する応答者であるかどうかを同定する方法

Country Status (15)

Country Link
US (1) US20100021424A1 (enExample)
EP (23) EP2390353A1 (enExample)
JP (1) JP2009538607A (enExample)
KR (1) KR20090017655A (enExample)
AR (1) AR061136A1 (enExample)
AU (1) AU2007256383B2 (enExample)
BR (1) BRPI0712497A2 (enExample)
CA (1) CA2653949A1 (enExample)
CL (1) CL2007001571A1 (enExample)
EA (1) EA200802242A1 (enExample)
ES (1) ES2539042T3 (enExample)
MX (1) MX2008015372A (enExample)
PE (1) PE20080742A1 (enExample)
TW (1) TW200817680A (enExample)
WO (1) WO2007140958A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013514090A (ja) * 2009-12-16 2013-04-25 日立化成株式会社 攻撃的及び防御的免疫マーカーのｅｘｖｉｖｏ誘導により宿主免疫機能を特徴付けるための方法
JP2015528698A (ja) * 2012-07-12 2015-10-01 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 少なくとも７個の遺伝子のサインを用いて、固形癌を患う患者の生存期間および処置に対する応答性を予測するための方法

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2227558A1 (en) * 2007-11-30 2010-09-15 GlaxoSmithKline Biologicals SA Method for classifying cancer patients as responder or non-responder to immunotherapy
GB0816867D0 (en) * 2008-09-15 2008-10-22 Glaxosmithkline Biolog Sa Method
GB2466025A (en) * 2008-12-08 2010-06-09 Univ Francois Rabelais De Tour C3/ITGAM polymorphisms and cancer prognosis
GB0917457D0 (en) * 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
EP2380991A1 (en) 2010-04-20 2011-10-26 Universitätsklinikum Hamburg-Eppendorf Method of determining the metastatic potential of a tumor
NZ608459A (en) * 2010-09-15 2015-10-30 Almac Diagnostics Ltd Molecular diagnostic test for cancer
KR101287600B1 (ko) * 2011-01-04 2013-07-18 주식회사 젠큐릭스 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법
US9926604B2 (en) 2011-10-14 2018-03-27 The Regents Of The University Of California Multiplex PCR-based testing of cutaneous squamous cell carcinoma and pseudoepitheliomatous hyperplasia and methods for distinguishing the same
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
BR112016014410A2 (pt) 2013-12-20 2018-02-20 The Broad Institute Inc. terapia de combinação com vacina de neoantígeno
US20170202478A1 (en) * 2014-07-03 2017-07-20 University Of Virginia Patent Foundation Systems and methods for identifying and profiling muscle patterns
US20170298443A1 (en) * 2014-09-25 2017-10-19 Moffitt Genetics Corporation Prognostic tumor biomarkers
EP3234193B1 (en) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
JP6489900B2 (ja) * 2015-03-30 2019-03-27 株式会社ジャパンディスプレイ 入力装置及び表示装置
BR112017024797A2 (pt) 2015-05-20 2018-08-07 The Broad Institute Inc. neoantígenos partilhados
JP2018520182A (ja) * 2015-07-14 2018-07-26 アトッサ ジェネティックス インク． 乳房障害を処置するための経乳頭方法及び組成物
WO2017040520A1 (en) 2015-08-31 2017-03-09 Hitachi Chemical Co., Ltd. Molecular methods for assessing urothelial disease
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CN118370809A (zh) 2017-04-03 2024-07-23 百欧恩泰美国公司 蛋白质抗原及其用途
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
GB201908565D0 (en) * 2019-06-14 2019-07-31 Cray Innovation Ab Method of stratifying subjects into sub-groups for therapeutic treatment
CN114540504B (zh) * 2022-04-27 2022-07-08 广州万德基因医学科技有限公司 用于预测肺鳞癌患者免疫疗效的标志物组及系统

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042286A1 (en) * 2005-10-11 2007-04-19 Merck Patent Gmbh Egfr dependent modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effects thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1001034B (el) * 1989-07-21 1993-03-31 Ortho Pharma Corp Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE156710T1 (de) 1992-06-25 1997-08-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6194388B1 (en) 1994-07-15 2001-02-27 The University Of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
CA2584482C (en) 1998-02-05 2012-03-27 Smithkline Beecham Biologicals S.A. Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
AU773204C (en) 1998-08-10 2005-05-19 Antigenics Llc Compositions of CPG and saponin adjuvants and methods thereof
BR0007840A (pt) 1999-01-29 2002-01-22 Corixa Corp Proteìnas de fusão her-2/neu
AU756398B2 (en) 1999-03-11 2003-01-09 Smithkline Beecham Biologicals (Sa) Novel compounds
EP1187629B1 (en) 1999-04-19 2004-09-22 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
ATE487733T1 (de) 2000-02-23 2010-11-15 Glaxosmithkline Biolog Sa Neue verbindungen
AUPR077900A0 (en) * 2000-10-13 2000-11-09 Tvw Telethon Institute For Child Health Research Immunodiagnosis
US20020076469A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
KR20030092003A (ko) * 2001-02-26 2003-12-03 게젤샤프트 퓌어 비오테크놀로기쉐 포르슝 엠베하(게베에프) 인터페론 조절 인자-1／인간 에스트로겐 수용체 융합단백질 및 암을 치료하기 위한 그의 용도
WO2002076469A1 (en) * 2001-03-27 2002-10-03 Baylor College Of Medicine A novel technology of intracellular delivery of dna oligonucleotides to improve drug activity
DE10127572A1 (de) * 2001-05-30 2002-12-05 Pathoarray Gmbh Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
EP2131198B1 (en) * 2001-09-20 2013-03-27 Board of Regents, The University of Texas System Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
WO2003050257A2 (en) * 2001-12-06 2003-06-19 University Of Florida Targeting leukemia cells
ATE447844T1 (de) 2002-02-04 2009-11-15 Corixa Corp Neue immuneffektor-verbindungen
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
ES2285174T3 (es) 2002-06-11 2007-11-16 Glaxosmithkline Biologicals S.A. Composiciones inmunogenicas.
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
WO2004076565A2 (en) * 2003-02-25 2004-09-10 Technical Knockout, Inc. Improved coated weight plates, dumbbells and method of manufacture
EP1605811A4 (en) * 2003-02-28 2008-06-11 Bayer Pharmaceuticals Corp EXPRESSION PROFILES FOR BREAST CANCER AND METHODS OF USE
WO2005098037A1 (en) * 2003-03-07 2005-10-20 Arcturus Bioscience, Inc. Breast cancer signatures
US20060265138A1 (en) 2003-03-14 2006-11-23 David Bowtell Expression profiling of tumours
US20040241725A1 (en) * 2003-03-25 2004-12-02 Wenming Xiao Lung cancer detection
US7598287B2 (en) * 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
US7640114B2 (en) * 2003-05-21 2009-12-29 The Wistar Institute Of Anatomy & Biology Method of diagnosis of cancer based on gene expression profiles in cells
CA2527285A1 (en) * 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
NZ543234A (en) 2003-05-30 2009-04-30 Astrazeneca Uk Ltd Marker genes and uses thereof to identify cancer patients that will respond to erbb tyrosine kinase inhibitors
US20050100933A1 (en) * 2003-06-18 2005-05-12 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
CN1842603B (zh) * 2003-06-27 2013-09-11 株式会社国际癌症免疫研究所 选择适于wt1疫苗患者的方法
EP1980629A3 (en) * 2003-08-28 2008-12-17 Ipsogen Identification of an erbb2 gene expression signature in breast cancers
CA2540894A1 (en) 2003-10-03 2005-04-14 Bayer Pharmaceuticals Corporation Gene expression profiles and methods of use
US20070110710A1 (en) * 2003-11-05 2007-05-17 New England Medical Center Hospitals, Inc. Treatment with immunoregulatory t cells
WO2005054496A1 (ja) * 2003-12-02 2005-06-16 Orient Cancer Therapy Co., Ltd. 細胞動態の検査方法
WO2005059543A1 (en) * 2003-12-12 2005-06-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor h963 (h963)
JP4974528B2 (ja) * 2004-02-09 2012-07-11 扶桑薬品工業株式会社 核酸検出方法およびその利用
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
US7332281B2 (en) * 2004-04-27 2008-02-19 Sagres Discovery, Inc. Therapeutic targets in cancer
MXPA06014771A (es) * 2004-06-17 2007-03-21 Mannkind Corp Perfiles de antigeno asociados a tumor en diagnosticos de cancer e inmunoterapia.
EP1786465A4 (en) * 2004-07-30 2009-01-21 Univ Oregon Health & Science METHODS FOR DETECTION AND TREATMENT OF AUTOIMMUNE DISORDERS
CA2587676A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US20060110371A1 (en) * 2004-11-23 2006-05-25 Institut Pasteur Control of indoleamine 2,3 deoxygenase expression and activity
EP1831684A4 (en) 2004-11-30 2009-03-11 Veridex Llc LUNGENKREBSPROGNOSTIK
US20070059720A9 (en) * 2004-12-06 2007-03-15 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients
WO2006073982A2 (en) * 2004-12-30 2006-07-13 Regents Of The University Of California Bispecific molecule comprising ligands for cell-surface protein and t-cell surface protein
WO2006091776A2 (en) 2005-02-25 2006-08-31 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
GB0504302D0 (en) 2005-03-02 2005-04-06 Univ Dublin Markers for melanoma
US20080193938A1 (en) 2005-04-01 2008-08-14 Yu Kun Materials And Methods Relating To Breast Cancer Classification
WO2006110585A2 (en) * 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. Cancer-related genes (prlr)
WO2006113671A2 (en) * 2005-04-15 2006-10-26 Oncomethylome Sciences, S.A. Methylation markers for diagnosis and treatment of cancers
US20090186024A1 (en) 2005-05-13 2009-07-23 Nevins Joseph R Gene Expression Signatures for Oncogenic Pathway Deregulation
WO2007008583A2 (en) * 2005-07-07 2007-01-18 Kohne David E Improved protein expression comparison assay results and applications
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007042286A1 (en) * 2005-10-11 2007-04-19 Merck Patent Gmbh Egfr dependent modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effects thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013514090A (ja) * 2009-12-16 2013-04-25 日立化成株式会社 攻撃的及び防御的免疫マーカーのｅｘｖｉｖｏ誘導により宿主免疫機能を特徴付けるための方法
JP2015528698A (ja) * 2012-07-12 2015-10-01 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 少なくとも７個の遺伝子のサインを用いて、固形癌を患う患者の生存期間および処置に対する応答性を予測するための方法
JP2019162138A (ja) * 2012-07-12 2019-09-26 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 少なくとも７個の遺伝子のサインを用いて、固形癌を患う患者の生存期間および処置に対する応答性を予測するための方法

Also Published As

Publication number Publication date
EA200802242A1 (ru) 2009-08-28
AR061136A1 (es) 2008-08-06
EP2390366A1 (en) 2011-11-30
EP2390357A1 (en) 2011-11-30
EP2390363A1 (en) 2011-11-30
EP2032719A2 (en) 2009-03-11
AU2007256383B2 (en) 2013-06-06
EP2390368A1 (en) 2011-11-30
WO2007140958A3 (en) 2008-07-03
EP2258874B1 (en) 2015-03-18
EP2390353A1 (en) 2011-11-30
WO2007140958A9 (en) 2009-11-26
MX2008015372A (es) 2009-03-23
EP2392671A1 (en) 2011-12-07
EP2392672A1 (en) 2011-12-07
EP2390360A1 (en) 2011-11-30
PE20080742A1 (es) 2008-08-06
EP2392673A1 (en) 2011-12-07
ES2539042T3 (es) 2015-06-25
EP2390365A1 (en) 2011-11-30
EP2390367A1 (en) 2011-11-30
EP2392675A1 (en) 2011-12-07
EP2390359A1 (en) 2011-11-30
EP2390364A1 (en) 2011-11-30
TW200817680A (en) 2008-04-16
EP2390358A1 (en) 2011-11-30
WO2007140958A2 (en) 2007-12-13
CL2007001571A1 (es) 2008-05-16
EP2390361A1 (en) 2011-11-30
EP2258874A1 (en) 2010-12-08
BRPI0712497A2 (pt) 2012-09-18
AU2007256383A1 (en) 2007-12-13
EP2390362A1 (en) 2011-11-30
EP2390369A1 (en) 2011-11-30
CA2653949A1 (en) 2007-12-13
US20100021424A1 (en) 2010-01-28
EP2390354A1 (en) 2011-11-30
EP2390355A1 (en) 2011-11-30
KR20090017655A (ko) 2009-02-18
EP2390356A1 (en) 2011-11-30

Similar Documents

Publication Publication Date Title
JP2009538607A (ja) 患者が免疫療法に対する応答者であるかどうかを同定する方法
CN113260633A (zh) 用于癌症免疫疗法的诊断方法和组合物
US20100247580A1 (en) Method for Classifying Cancer Patients as Responder or Non-Responder to Immunotherapy
US20110070268A1 (en) Method
AU2020201779A1 (en) Method for using gene expression to determine prognosis of prostate cancer
CN101501218A (zh) 用于鉴定患者是否将是免疫治疗的反应者的方法
US20100166783A1 (en) Method
HK40058894A (en) Diagnostic methods and compositions for cancer immunotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120703

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120927

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130423

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140325